Hepatitis Monthly

Published by: Kowsar

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir

Xin Wei 1 , Chao Fan 1 , Yun Zhou 1 , Wenzhen Kang 1 , Jiuping Wang 1 , Li Sun 1 , Linxu Wang 1 , Meijuan Peng 1 , Jianqi Lian 1 , Zhansheng Jia 1 and Chunqiu Hao 1 , *
Authors Information
1 Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shannxi Province, China
Article information
  • Hepatitis Monthly: January 01, 2016, 16 (1); e31278
  • Published Online: January 23, 2016
  • Article Type: Research Article
  • Received: July 5, 2015
  • Revised: October 10, 2015
  • Accepted: November 21, 2015
  • DOI: 10.5812/hepatmon.31278

To Cite: Wei X, Fan C, Zhou Y, Kang W, Wang J, et al. The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir, Hepat Mon. 2016 ; 16(1):e31278. doi: 10.5812/hepatmon.31278.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009; 122(1): 3-4[PubMed]
  • 2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 4. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007; 11(4): 797-816[DOI][PubMed]
  • 5. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010; 139(2): 474-82[DOI][PubMed]
  • 6. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int. 2012; 32(9): 1333-41[DOI][PubMed]
  • 7. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI][PubMed]
  • 8. Hui CK, Lau GK. Immune system and hepatitis B virus infection. J Clin Virol. 2005; 34 Suppl 1-8[PubMed]
  • 9. Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011; 54(5): 1591-9[DOI][PubMed]
  • 10. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011; 66(12): 2715-25[DOI][PubMed]
  • 11. Menendez-Arias L, Alvarez M, Pacheco B. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014; 8: 1-9[DOI][PubMed]
  • 12. Minde Z, Yimin M, Guangbi Y, JinLin H, Hao W, Hong R, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int. 2012; 32(1): 137-46[DOI][PubMed]
  • 13. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther. 2008; 13(3): 381-8[PubMed]
  • 14. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009; 51(2): 403-10[DOI][PubMed]
  • 15. Zhou X, Kuang X, Fan K, Zhang C, Deng G, Wang H, et al. Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance. J Med Virol. 2012; 84(7): 1030-6[DOI][PubMed]
  • 16. Chien RN. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective. J Gastroenterol Hepatol. 2010; 25(5): 852-7[DOI][PubMed]
  • 17. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol. 2009; 50(4): 674-83[DOI][PubMed]
  • 18. Seo SY, Kim IH, Sohn JY, Lee S, Kim SH, Kim SW, et al. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. Intervirology. 2014; 57(1): 8-16[DOI][PubMed]
  • 19. Wang X, Zhang C, Zhu Y, Xiong Y, Wang Y. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. Antiviral Res. 2014; 103: 71-7[DOI][PubMed]
  • 20. Lavocat F, Deny P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, et al. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol. 2013; 59(4): 684-95[DOI][PubMed]
  • 21. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2014; 60(4): 715-22[DOI][PubMed]
  • 22. Keskin O, Ormeci AC, Baran B, Kabacam G, Tuzun A, Karatayli E, et al. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. Antivir Ther. 2014; 19(6): 543-50[DOI][PubMed]
  • 23. Lampertico P. Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B: From guidelines to field practice. J Hepatol. 2009; 50(4): 644-7[DOI][PubMed]
  • 24. Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, et al. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Antivir Ther. 2012; 17(4): 701-9[DOI][PubMed]
  • 25. Chen EQ, Zhou TY, Bai L, Wang JR, Yan LB, Liang LB, et al. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. Antivir Ther. 2012; 17(6): 973-9[DOI][PubMed]
  • 26. Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat. 2013; 20 Suppl 1: 40-5[DOI][PubMed]
  • 27. He D, Li M, Guo S, Zhu P, Huang H, Yan G, et al. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. J Clin Immunol. 2013; 33(7): 1240-9[DOI][PubMed]
  • 28. Chan HL, Wong VW, Chim AM, Wong GL, Chan HY, Sung JJ. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). Antivir Ther. 2008; 13(4): 555-62[PubMed]
  • 29. Zhang XQ, Zhang HY, You JP, Mao Q. Efficacy of pegylated interferon alpha2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Virol J. 2013; 10: 21[DOI][PubMed]
  • 30. Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther. 2011; 34(4): 424-31[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments